StockNews.com began coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a report issued on Thursday. The firm issued a hold rating on the stock. Separately, HC Wainwright reiterated a buy rating and issued a $11.00 target price on shares of Galectin Therapeutics in a research note on Tuesday, August 15th. Get Our […]
StockNews.com initiated coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research note released on Wednesday morning. The firm issued a hold rating on the stock. Separately, HC Wainwright restated a buy rating and set a $11.00 price objective on shares of Galectin Therapeutics in a research report on Tuesday, August 15th. […]
StockNews.com assumed coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research note published on Sunday. The brokerage issued a hold rating on the stock. Separately, HC Wainwright restated a buy rating and set a $11.00 price target on shares of Galectin Therapeutics in a report on Tuesday, August 15th. Read Our […]
StockNews.com initiated coverage on shares of Galectin Therapeutics (NASDAQ:GALT – Free Report) in a research note published on Saturday morning. The brokerage issued a hold rating on the stock. Separately, HC Wainwright reissued a buy rating and issued a $11.00 price objective on shares of Galectin Therapeutics in a research report on Tuesday, August 15th. […]
Several brokerages have updated their recommendations and price targets on shares of Galectin Therapeutics (NASDAQ: GALT) in the last few weeks: 8/19/2023 – Galectin Therapeutics is now covered by analysts at StockNews.com. They set a “hold” rating on the stock. 8/15/2023 – Galectin Therapeutics had its “buy” rating reaffirmed by analysts at HC Wainwright. They […]